The study, which focused on the rare cancers synovial sarcoma and myxoid round cell liposarcoma (MRCLS), is published in The Lancet. "When these rare sarcomas have spread, patients have few ...

Researchers observed responses in patients with synovial sarcoma or myxoid/round cell liposarcoma treated with lete-cel.

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The FDA has given accelerated approval to a groundbreaking T cell-based therapy from Adaptimmune for synovial sarcoma, becoming the first new treatment for the rare soft tissue cancer in more than ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Synovial Sarcoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering A groundbreaking insight into the Synovial ...